当前位置: 首页 >> 检索结果
3361. Usefulness of Fibrosis-4 Index for the stratification of the risk of hepatocellular carcinoma development in patients with chronic hepatitis B on long-term follow-up: a single center experience.
作者: Eleonora DI Leo.;Chiara Rosso.;Antonella Olivero.;Gian P Caviglia.
来源: Minerva Gastroenterol (Torino). 2023年69卷4期574-576页 3362. A Model to Eliminate Viral Hepatitis Infection in Migrants: A Prospective, Multicenter Study in Southern Italy.
作者: Mariantonietta Pisaturo.;Loredana Alessio.;Stefania de Pascalis.;Vincenzo Messina.;Lorenzo Onorato.;Nicola Coppola.; .
来源: Gastroenterology. 2024年166卷1期191-193.e2页 3364. Antireflux Surgery Versus Antireflux Medication and Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus.
作者: Johan Hardvik Åkerström.;Giola Santoni.;My von Euler Chelpin.;Eivind Ness-Jensen.;Joonas H Kauppila.;Dag Holmberg.;Jesper Lagergren.
来源: Gastroenterology. 2024年166卷1期132-138.e3页
Antireflux treatment is recommended to reduce esophageal adenocarcinoma in patients with Barrett's esophagus. Antireflux surgery (fundoplication) counteracts gastroesophageal reflux of all types of carcinogenic gastric content and reduces esophageal acid exposure to a greater extent than antireflux medication (eg, proton pump inhibitors). We examined the hypothesis that antireflux surgery prevents esophageal adenocarcinoma to a larger degree than antireflux medication in patients with Barrett's esophagus.
3371. Treatment of acute mesenteric ischemia between 2010 and 2020 - a German nation-wide study.
作者: Stefanie Bette.;Osama Habeeballah.;Jan H Luitjens.;Thomas Kroencke.;Christian Scheurig-Muenkler.;Josua A Decker.
来源: BMC Gastroenterol. 2023年23卷1期300页
Aim of this study was to analyze long-term trends of hospitalizations, treatment regimen and in-hospital mortality of in-patients with acute mesenteric ischemia (AMI) over the past decade and effects of the SARS-CoV2-pandemic.
3372. Prevalence of vomiting and nausea and associated factors after chronic and acute gluten exposure in celiac disease.
作者: Iida Ahonen.;Pilvi Laurikka.;Sara Koskimaa.;Heini Huhtala.;Katri Lindfors.;Katri Kaukinen.;Kalle Kurppa.;Laura Kivelä.
来源: BMC Gastroenterol. 2023年23卷1期301页
Vomiting and nausea seem to be relatively specific symptoms related to gluten ingestion in treated celiac disease. However, the overall prevalence and associated factors of these symptoms after chronic gluten exposure at celiac disease diagnosis and acute re-exposure during gluten challenge remain obscure.
3373. The influence of muscle performance and fatigue on prognosis in patients with compensated liver disease.
作者: Ulrika Ekerfors.;Magnus Simrén.;Hanns-Ulrich Marschall.;Daghan Demir.;Axel Josefsson.
来源: BMC Gastroenterol. 2023年23卷1期302页
Poor muscle function is associated with a negative prognosis in advanced liver disease but the impact in compensated chronic liver disease is unknown. Similar prognostic uncertainty applies to fatigue. We aimed to assess the prognostic value of muscle performance and fatigue in a cohort of patients with compensated chronic liver disease.
3374. Is empiric proton pump inhibition in patients with symptoms of extraesophageal gastroesophageal reflux justified?
The prevalence of gastroesophageal reflux disease (GERD) has had a marked increase in Western countries with a paralleling interest in extraesophageal (EE) manifestations of GERD, including laryngopharyngeal reflux (LPR). There are considerable differences in clinical practice between gastroenterologists, otolaryngologists and pulmonologists.
3375. Multicentre prospective study to evaluate effectiveness and safety of gel-forming and hyaluronic-acid containing chewable tablets as add-on treatment in patients with gastroesophageal reflux disease (GERD) symptoms and unsatisfying proton pump inhibitor therapy.
作者: Manfred Gross.;Dennis Neuschwander.;Lisa Steffens.;Jörn Thomsen.;Kristina Röschmann-Doose.
来源: BMC Gastroenterol. 2023年23卷1期304页
Gastroesophageal reflux disease (GERD) is a common disease which in the majority of patients is treated with proton pump inhibitors (PPI). However, up to 45% of the patients remain symptomatic on a standard dose of PPI. This study investigated the effectiveness and safety of an add-on therapy with the gel-forming chewable tablet Sobrade® in patients unsatisfied with PPI treatment. The bioadhesive gel covers the oesophagus and thereby protects the mucosa from reflux events.
3377. Cystic tumor ablation with different concentrations of lauromacrogol solution in an animal model.
作者: Fei Gao.;Huikai Li.;Xiuxue Feng.;Chen DU.;Ke Han.;Ningli Chai.;Enqiang Linghu.
来源: Minerva Gastroenterol (Torino). 2024年70卷4期422-429页
Lauromacrogol, as a sclerosing agent, can induce aseptic inflammation and fibrous tissue proliferation to achieve sclerotherapy. Lauromacrogol is widely used not only for vascular sclerotherapy but also for the treatment of different cystic tumors. To evaluate the efficacy and safety of cystic tumor ablation with different concentrations of lauromacrogol solution in a rat endometriosis model, and explore the advantages and disadvantages of this model in simulating pancreatic cystic neoplasm.
3378. Transhepatectomy combined with arterial chemoembolization and transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a clinical prognostic analysis.
作者: Xin Liu.;Haodong Li.;Fei Wang.;Ke Su.;Bingsheng He.;Jie He.;Jiaqi Zhong.;Yunwei Han.;Zhenjiang Li.
来源: BMC Gastroenterol. 2023年23卷1期299页
The prognosis of patients undergoing hepatectomy combined with transarterial chemoembolization (TACE) and TACE alone was examined in order to better understand the role of hepatectomy in the treatment of hepatocellular carcinoma (HCC). In this work, we also created a model and investigated the variables influencing overall survival (OS) in HCC patients.
3379. The efficacy of non-anesthesiologist-administered propofol sedation with a target-controlled infusion system during double-balloon endoscopic retrograde cholangiopancreatography.
作者: Kazuya Miyamoto.;Kazuyuki Matsumoto.;Taisuke Obata.;Ryosuke Sato.;Akihiro Matsumi.;Kosaku Morimoto.;Taiji Ogawa.;Hiroyuki Terasawa.;Yuki Fujii.;Tatsuhiro Yamazaki.;Daisuke Uchida.;Shigeru Horiguchi.;Koichiro Tsutsumi.;Hironari Kato.;Motoyuki Otsuka.
来源: BMC Gastroenterol. 2023年23卷1期296页
The sedation method used during double-balloon endoscopic retrograde cholangiopancreatography (DB-ERCP) differs among countries and/or facilities, and there is no established method. This study aimed to evaluate the efficacy of non-anesthesiologist-administered propofol (NAAP) sedation using a target-controlled infusion (TCI) system during DB-ERCP.
3380. Relapse rate and predictors of relapse after cessation of glucocorticoid maintenance therapy in type 1 autoimmune pancreatitis: a multicenter retrospective study.
作者: Yusuke Kiyoshita.;Yasutaka Ishii.;Masahiro Serikawa.;Keiji Hanada.;Tamito Sasaki.;Yoshifumi Fujimoto.;Atsushi Yamaguchi.;Ken Hirao.;Bunjiro Noma.;Tomoyuki Minami.;Akihito Okazaki.;Masanobu Yukutake.;Teruo Mouri.;Tomofumi Tsuboi.;Yumiko Tatsukawa.;Shinya Nakamura.;Tetsuro Hirano.;Juri Ikemoto.;Sho Saeki.;Yosuke Tamura.;Sayaka Miyamoto.;Masaru Furukawa.;Kazuki Nakmura.;Yumiko Yamashita.;Noriaki Iijima.;Shiro Oka.
来源: BMC Gastroenterol. 2023年23卷1期295页
Type 1 autoimmune pancreatitis responds well to glucocorticoid therapy with a high remission rate. Moreover, glucocorticoid maintenance therapy can help prevent relapse. However, the relapse rate following cessation of long-term glucocorticoid therapy is unknown. The aim of this study was to clarify the relapse rate and predictors of relapse following long-term glucocorticoid therapy cessation.
|